Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial

Lorenzana, Sarah B.; Hughes, Michael D.; Grinsztejn, Beatriz; More

AIDS . 26(9):1083-1093, June 1, 2012.

Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration

Croteau, David; Best, Brookie M.; Letendre, Scott; More

AIDS . 26(7):890-893, April 24, 2012.

CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy

Ellis, Ronald J.; Badiee, Jayraan; Vaida, Florin; More

AIDS . 25(14):1747-1751, September 10, 2011.

Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression

Havlir, Diane V.; Gilbert, Peter B.; Bennett, Kara; More

AIDS . 15(11):1379-1388, July 27, 2001.

Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients

Zhou, Xiao-Jian; Havlir, Diane V.; Richman, Douglas D.; More

AIDS . 14(18):2869-2876, December 22, 2000.

The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements

Brambilla, Donald; Reichelderfer, Patricia S.; Bremer, James W.; More

AIDS . 13(16):2269-2279, November 12, 1999.

The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine.

Jacobson, Mark A.; Gruttola, Victor De; Jean-Marie Arduino, Mohan Reddy; More

AIDS . 9(7):727-734, July 1995.